Genetics Institute Inc. has licensed from British TechnologyGroup U.S.A. Inc. rights to produce recombinant human FactorIX protein from cell culture to treat hemophilia B, thecompanies announced Monday.

Hemophilia B, caused by a defect or deficiency of Factor IX,afflicts 2,000-3,000 people in the U.S. GI (NASDAQ:GENIZ) ofCambridge, Mass., said that combining its genetic engineeringand cell culture technology with the Factor IX patent rights willenable GI to begin development of a recombinant human FactorIX product to treat hemophilia B.

(c) 1997 American Health Consultants. All rights reserved.